Nile Pharmaceuticals results, Q4 2025
Net profit, assets, equity and cash flow for Q4 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit1.07 millionEGP · −98.8% vs the same period a year earlier
Shareholders' equity743 millionEGP · +58.5% vs the same period a year earlier
Operating cash flow50.54 millionEGP · −80.9% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q4 2025 was about 1.07 million EGP, down −98.8% from 90.23 million EGP in Q4 2024.
- Operating cash flow for Q4 2025 was positive at 50.54 million EGP.
Key lines against the same period a year earlier
This periodQ4 2024Change
Net profit1.07 million90.23 million−98.8%
Gross profit857 million298 million+187.2%
Total assets—1.47 billion—
Total liabilities—1 billion—
Shareholders' equity743 million469 million+58.5%
Total liabilities and equity2.32 billion1.47 billion+57.5%
Operating cash flow50.54 million264 million−80.9%
Investing cash flow-183 million-420 million+56.4%
Financing cash flow52.89 million303 million−82.6%
Net change in cash—-121 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy